Balwinder Singh

Psychiatry — Mayo Clinic (United States, Rochester), United States

LeadR Profile

Balwinder Singh Mayo Clinic (United States, Rochester) United States
1 676 ScienceLeadR Reputation 1676
Network Map

Psychiatry

Subspecialties: Pharmacy - Neurology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2011 - 2026

Source: PubMed

Mayo Clinic (United States, Rochester)

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 469

Citations

Citations: 10 980 1st author: 95 Last author: 161 Unique author: 16


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.
depression, brain, ketamine, therapeutics
Neuropsychopharmacology20260
SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.
kidney diseases, glucagon-like peptide 1, sodium-glucose transporter 2 inhibitors, bipolar disorder, mortality, glucagon-like peptide-1 receptor, hospitalization, cohort studies, kidney, therapeutics, affective symptoms, renal replacement therapy
J Affect Disord20260
Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial.
antidepressive agents, biological psychiatry, ketamine, depressive disorder, metabolomics, therapeutics, hydrocortisone, depressive disorder, major
World J Biol Psychiatry20260
GLP-1 Receptor Agonists, Lithium, and the Kidneys: A Tale of Two Signals.
glucagon-like peptide 1, glucagon-like peptide-1 receptor, kidney, psychopharmacology
J Clin Psychopharmacol20260
Psychotherapy, Pharmacotherapy, and Neuromodulatory Interventions in Operational Definitions of Treatment-Resistant Depression: Reply to De Oliveira Reis et al.
depression, psychotherapy, drug therapy, therapeutics, depressive disorder, treatment-resistant, psychiatry
J Clin Psychiatry20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

N/A 3
Phase 2 3
Early Phase 1 1
Phase 4 1

By status:

Recruiting 4
Completed 2
Active not recruiting 1
Terminated 1

By type:

Interventional 7
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 2
multicentric5to9 3
multicentricup10 0

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B cell Non Hodgkin Lymphoma Before CAR T cell Therapy
NCT06834373 — ligases, cells, lymphoma, follicular, ubiquitin, bone marrow, blood, hodgkin disease, lymphoma, b-cell, pharmaceutical preparations, tomography, lymphoma, germinal center, lymphoma, large b-cell, diffuse, positron-emission tomography, neoplasms, blood component removal, leukapheresis, biopsy, positron emission tomography computed tomography, immunotherapy, rituximab, receptors, antigen, leukocytes, receptors, chimeric antigen, antibodies, monoclonal, immunotherapy, adoptive, specimen handling, lymphoma, non-hodgkin, blood cells, therapeutics, ubiquitin-protein ligases, histiocytes, t-lymphocytes, b-lymphocytes, receptors, antigen, t-cell, biosimilar pharmaceuticals, car-t cell, bone and bones
Phase 2Recruiting2025
Intravenous Ketamine for Treatment Resistant Depression
NCT06668571 — depression, saline solution, ketamine, solutions, depressive disorder, body weight, therapeutics, depressive disorder, treatment-resistant, depressive disorder, major
Phase 2Recruiting2025
Understanding the Mechanisms of Clonal and Non clonal Cytopenia Following CAR T Therapy for Multiple Myeloma or CD19 Lymphoproliferative Disorder (LPD)
NCT06630104 — cells, research design, genes, genetic testing, bone marrow, blood, follow-up studies, chromatin immunoprecipitation sequencing, neoplasms, chromatin immunoprecipitation, chromatin, electronic health records, genetic counseling, signs and symptoms, multiple myeloma, immunoprecipitation, specimen handling, records, therapeutics, lymphoproliferative disorders, counseling, receptors, antigen, t-cell, cytopenia, bone and bones
N/ARecruiting2024
Evaluating the Association Among Changes in Gut Microbiome Fatigue and Chemotherapy Induced Nausea in Early Stage Breast Cancer
NCT05417867 — blood, breast neoplasms, neoplasms, drug therapy, vomiting, fatigue, breast, nausea, specimen handling, gastrointestinal microbiome, chemotherapy, carcinoma
N/ARecruiting2021

LeadR Networks

Main global connection map